Several other studies have confirmed the upregulation of the receptor tyrosine kinases EGFR, PDGFRA and PDGFRB in SS that can be targeted by specific small molecule inhibitors [120–127]. This evidence concerns the gene PDGFRA and synovial sarcoma.